Clinical Trials Logo

Macular Oedema clinical trials

View clinical trials related to Macular Oedema.

Filter by:
  • None
  • Page 1

NCT ID: NCT02661711 Active, not recruiting - Clinical trials for Retinitis Pigmentosa

Aflibercept for Macular Oedema With Underlying Retinitis Pigmentosa (AMOUR) Study

AMOUR
Start date: March 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the safety and efficacy of intravitreal injections of Aflibercept (Eylea) in treating Cystoid Macula Oedema (CMO) in patients with underlying Retinitis Pigmentosa (RP).

NCT ID: NCT01566526 Completed - Clinical trials for Retinal Vein Occlusion

Retrospective Data Collection Study in Patients Receiving Two or More OZURDEX® Injections for Macular Oedema Secondary to Retinal Vein Occlusion

Start date: March 2012
Phase: N/A
Study type: Observational

The purpose of this study is to use retrospective data to evaluate the efficacy, safety and re-injection interval of OZURDEX® in the treatment of macular oedema due to retinal vein occlusion (RVO) in patients who received OZURDEX® as part of the Belgium Medical Needs Program.

NCT ID: NCT01257815 Completed - Clinical trials for Diabetic Retinopathy

Ranibizumab Treatment of Diabetic Macular Oedema With Bimonthly Monitoring After a Phase of Initial Treatment

RELIGHT
Start date: January 2011
Phase: Phase 4
Study type: Interventional

This study evaluates a new investigational treatment regimen of three consecutive monthly doses of ranibizumab followed by an as-needed treatment regimen, with monthly follow-up for the first three months then two-monthly follow-up until 18 months in patients with visual impairment due to diabetic macular oedema.The aim of the study is to determine if this treatment regimen is effective and safe in these patients.

NCT ID: NCT00403026 Recruiting - Clinical trials for Proliferative Diabetic Retinopathy

Intravitreal Bevacizumab for Retinal Disorders

Start date: August 2006
Phase: N/A
Study type: Interventional

Bevacizumab is an anti-VEGF agent used in approved for use in metastatic colorectal carcinoma (FDA Approved). This study analyzes the safety and efficacy of off-label Intravitreal Injection of bevacizumab (Avastin) for CNVM, Macular oedema due to diabetic retinopathy, vascular occlusion and other retinal disorders.